Misuk An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Misuk An has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- So Young Choi
Division of Quarantine Policy, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea
3 shared publications - Boyeong Ryu
Seoul Center for Infectious Disease Control, Seoul, Korea.; Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Minjeong Jang
Korea Dis Control & Prevent Agcy, Data Anal Team, Cheongju, South Korea
2 shared publications - Se-Jin Jeong
Division of Disease Control Research Planning, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea
2 shared publications - Seong-Sun Kim
Division of Epidemiological Data Analysis, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea
2 shared publications - 선경 백
질병관리청 질병데이터과학분석관 질병관리연구기획담당
2 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 19 (1) , 1-12
의료현장감염대응역량고도화기술개발 사업 관리 현황
안미숙, 이혜영, 정세진, 이호진, 백선경. Public Health Weekly Report 2026;19:1-12. https://doi.org/10.56786/PHWR.2026.19.1.1
- 2 December 2025
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 19 (1) , 1-12
Open Access의료현장감염대응역량고도화기술개발 사업 관리 현황
안미숙, 이혜영, 정세진, 이호진, 백선경. Public Health Weekly Report 2026;19:1-12. https://doi.org/10.56786/PHWR.2026.19.1.1
- Open Access
- 13 June 2025
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 18 (28) , 1054-1066
범부처감염병방역체계고도화R&D사업(2023–2027년) 운영 현황: 질병관리청 소관 중심으로
안미숙, 이혜영, 백선경. Public Health Weekly Report 2025;18:1054-66. https://doi.org/10.56786/PHWR.2025.18.28.2
- 13 June 2025
- Published by Korea Disease Control and Prevention Agency (Public Health Weekly Report) in Public Health Weekly Report
- Vol. 18 (28) , 1054-1066
Open Access범부처감염병방역체계고도화R&D사업(2023–2027년) 운영 현황: 질병관리청 소관 중심으로
안미숙, 이혜영, 백선경. Public Health Weekly Report 2025;18:1054-66. https://doi.org/10.56786/PHWR.2025.18.28.2
- Open Access
- 28 February 2025
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 16 (1) , 81-88
Characteristics and trends of severe/critical COVID-19 cases in the Republic of Korea (January 2020 to August 2023)
Objectives: We analyzed the demographic and clinical characteristics of patients diagnosed with coronavirus disease 2019 (COVID-19), focusing specifically on severe/critical cases, and assessed the trends and rates of severity and fatality among these patients in the Republic of Korea.Methods: Clinical data on patients with COVID-19 from January 20, 2020 to August 30, 2023 were collected from the Korea Disease Control and Prevention Agency’s database. We identified patients who progressed to severe/critical conditions and analyzed their demographic and clinical profiles. Severity and fatality rates were calculated and compared annually to track the disease progression over time.Results: During the surveillance period, 34,572,554 COVID-19 cases were confirmed, among whom 38,112 (0.11%) progressed to severe/critical conditions. Most severe/critical cases occurred in individuals aged ≥60 years, with a notable increase in patients aged ≥80 years from 2022. The overall severity rate was 0.19%, with a fatality rate of 0.10%. However, the severity of cases gradually diminished during the study period. In 2022, the severity and fatality rates decreased to 0.14% and 0.09%, respectively. In 2023, while the severity rate remained stable at 0.15%, the fatality rate further decreased to 0.06%. Notably, throughout the study period, individuals aged ≥80 years had a significantly higher severity rate (2.44%), with a fatality rate of 1.75%.Conclusion: These findings underscore the importance of prioritizing protection and management strategies for older adults and high-risk groups to mitigate the impact of COVID-19. Continued surveillance and analysis are essential to effectively control COVID-19 and minimize its burden on public health.
- 28 February 2025
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 16 (1) , 81-88
Open AccessCharacteristics and trends of severe/critical COVID-19 cases in the Republic of Korea (January 2020 to August 2023)
Objectives: We analyzed the demographic and clinical characteristics of patients diagnosed with coronavirus disease 2019 (COVID-19), focusing specifically on severe/critical cases, and assessed the trends and rates of severity and fatality among these patients in the Republic of Korea.Methods: Clinical data on patients with COVID-19 from January 20, 2020 to August 30, 2023 were collected from the Korea Disease Control and Prevention Agency’s database. We identified patients who progressed to severe/critical conditions and analyzed their demographic and clinical profiles. Severity and fatality rates were calculated and compared annually to track the disease progression over time.Results: During the surveillance period, 34,572,554 COVID-19 cases were confirmed, among whom 38,112 (0.11%) progressed to severe/critical conditions. Most severe/critical cases occurred in individuals aged ≥60 years, with a notable increase in patients aged ≥80 years from 2022. The overall severity rate was 0.19%, with a fatality rate of 0.10%. However, the severity of cases gradually diminished during the study period. In 2022, the severity and fatality rates decreased to 0.14% and 0.09%, respectively. In 2023, while the severity rate remained stable at 0.15%, the fatality rate further decreased to 0.06%. Notably, throughout the study period, individuals aged ≥80 years had a significantly higher severity rate (2.44%), with a fatality rate of 1.75%.Conclusion: These findings underscore the importance of prioritizing protection and management strategies for older adults and high-risk groups to mitigate the impact of COVID-19. Continued surveillance and analysis are essential to effectively control COVID-19 and minimize its burden on public health.
- Open Access
- 30 April 2024
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 15 (2) , 137-149
Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study
Objectives: This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older. Using real-world data, the period during which the BN.1 Omicron variant was dominant was compared to the period dominated by the BA.5 variant.Methods: In this retrospective cohort study, data were collected regarding 2,665,281 patients infected with severe acute respiratory syndrome coronavirus 2 between July 24, 2022, and March 31, 2023. Propensity score matching was utilized to match patients who received nirmatrelvir/ritonavir in a 1:4 ratio between BN.1 and BA.5 variant groups. Multivariable logistic regression analysis was employed to assess the effects of nirmatrelvir/ritonavir within these groups.Results: Compared to the prior period, the efficacy of nirmatrelvir/ritonavir did not significantly differ during the interval of Omicron BN.1 variant dominance in the Republic of Korea. Among patients treated with nirmatrelvir/ritonavir, a significantly lower risk of mortality was observed in the BN.1 group (odds ratio [OR], 0.698; 95% confidence interval [CI], 0.557–0.875) compared to the BA.5 group. However, this treatment did not significantly reduce the risk of severe or critical illness, including death, for those in the BN.1 group (OR, 0.856; 95% CI, 0.728–1.007).Conclusion: Nirmatrelvir/ritonavir has maintained its effectiveness against COVID-19, even with the emergence of the BN.1 Omicron subvariant. Consequently, we strongly recommend the administration of nirmatrelvir/ritonavir to patients exhibiting COVID-19-related symptoms, irrespective of the dominant Omicron variant or their vaccination status, to mitigate disease severity and decrease the risk of mortality.
- 30 April 2024
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 15 (2) , 137-149
Open AccessEffect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study
Objectives: This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older. Using real-world data, the period during which the BN.1 Omicron variant was dominant was compared to the period dominated by the BA.5 variant.Methods: In this retrospective cohort study, data were collected regarding 2,665,281 patients infected with severe acute respiratory syndrome coronavirus 2 between July 24, 2022, and March 31, 2023. Propensity score matching was utilized to match patients who received nirmatrelvir/ritonavir in a 1:4 ratio between BN.1 and BA.5 variant groups. Multivariable logistic regression analysis was employed to assess the effects of nirmatrelvir/ritonavir within these groups.Results: Compared to the prior period, the efficacy of nirmatrelvir/ritonavir did not significantly differ during the interval of Omicron BN.1 variant dominance in the Republic of Korea. Among patients treated with nirmatrelvir/ritonavir, a significantly lower risk of mortality was observed in the BN.1 group (odds ratio [OR], 0.698; 95% confidence interval [CI], 0.557–0.875) compared to the BA.5 group. However, this treatment did not significantly reduce the risk of severe or critical illness, including death, for those in the BN.1 group (OR, 0.856; 95% CI, 0.728–1.007).Conclusion: Nirmatrelvir/ritonavir has maintained its effectiveness against COVID-19, even with the emergence of the BN.1 Omicron subvariant. Consequently, we strongly recommend the administration of nirmatrelvir/ritonavir to patients exhibiting COVID-19-related symptoms, irrespective of the dominant Omicron variant or their vaccination status, to mitigate disease severity and decrease the risk of mortality.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (40) , e267
Estimating Excess Mortality During the COVID-19 Pandemic Between 2020–2022 in Korea
Jang M, et al. J Korean Med Sci. 2024 Aug;39(40):e267. https://doi.org/10.3346/jkms.2024.39.e267
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (40) , e267
Open AccessEstimating Excess Mortality During the COVID-19 Pandemic Between 2020–2022 in Korea
Jang M, et al. J Korean Med Sci. 2024 Aug;39(40):e267. https://doi.org/10.3346/jkms.2024.39.e267